TUB Stock Overview
Operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Financière de Tubize SA Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €107.20 |
52 Week High | €109.20 |
52 Week Low | €60.80 |
Beta | 0.44 |
11 Month Change | 8.72% |
3 Month Change | 17.03% |
1 Year Change | 53.80% |
33 Year Change | 23.50% |
5 Year Change | 77.48% |
Change since IPO | 1,813.60% |
Recent News & Updates
Shareholder Returns
TUB | BE Pharmaceuticals | BE Market | |
---|---|---|---|
7D | 3.5% | -1.5% | 0.9% |
1Y | 53.8% | 22.7% | 5.8% |
Return vs Industry: TUB exceeded the Belgian Pharmaceuticals industry which returned 22.7% over the past year.
Return vs Market: TUB exceeded the Belgian Market which returned 5.8% over the past year.
Price Volatility
TUB volatility | |
---|---|
TUB Average Weekly Movement | 2.9% |
Pharmaceuticals Industry Average Movement | 4.8% |
Market Average Movement | 3.5% |
10% most volatile stocks in BE Market | 6.1% |
10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: TUB has not had significant price volatility in the past 3 months.
Volatility Over Time: TUB's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1928 | n/a | Eric Nys | www.financiere-tubize.be |
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Financière de Tubize SA Fundamentals Summary
TUB fundamental statistics | |
---|---|
Market cap | €4.77b |
Earnings (TTM) | €88.15m |
Revenue (TTM) | n/a |
54.1x
P/E Ratio0.0x
P/S RatioIs TUB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TUB income statement (TTM) | |
---|---|
Revenue | €0 |
Cost of Revenue | €2.03m |
Gross Profit | -€2.03m |
Other Expenses | -€90.18m |
Earnings | €88.15m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
Earnings per share (EPS) | 1.98 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 4.4% |
How did TUB perform over the long term?
See historical performance and comparison